Luteolin supplementation adjacent to aspirin treatment reduced dimethylhydrazine-induced experimental colon carcinogenesis in rats

Tumor Biology

Volumn 36, Issue 2, 2015, Pages 1179-1190

  Osman, Neamt H A ^a   Said, Usama Z ^a   El Waseef, Ahmed M ^b   Ahmed, Esraa S A ^a  

^a NATIONAL CENTER FOR RADIATION RESEARCH AND TECHNOLOGY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

Aspirin; Colon; Dimethylhydrazine; Luteolin (LUT)

Indexed keywords

ACETYLSALICYLIC ACID; CARCINOEMBRYONIC ANTIGEN; CYCLOOXYGENASE 2; DIMETHYLHYDRAZINE; LUTEOLIN; ANTINEOPLASTIC AGENT; ANTIOXIDANT; PTGS2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON CARCINOGENESIS; COLON POLYP; CONTROLLED STUDY; KIDNEY FUNCTION TEST; KIDNEY HEMORRHAGE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SUPPLEMENTATION; ANIMAL; BIOSYNTHESIS; CARCINOGENESIS; CHEMICALLY INDUCED; COLONIC NEOPLASMS; DRUG EFFECTS; HUMAN; LIPID PEROXIDATION; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIOXIDANTS; ASPIRIN; CARCINOEMBRYONIC ANTIGEN; CARCINOGENESIS; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; DIMETHYLHYDRAZINES; HUMANS; LIPID PEROXIDATION; LUTEOLIN; NEOPLASMS, EXPERIMENTAL; OXIDATIVE STRESS; RATS; RATS, WISTAR;

EID: 84925533272     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2678-2     Document Type: Article

References (89)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277–300.
2. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. Engl J Med. 2000;42:1960–8.
3. Jain M, Cook GM, Davis FG, Grace MG, Howe GR, Miller AB. A case-control study of diet and colorectal cancer. Int J Cancer. 1980;26:757–68.
4. English DR, MacInnis RJ, Hodge AM, Hopper JL, Haydon AM, Giles GG. Red meat, chicken, and fish consumption and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:1509–14.
5. Larsson SC, Rafter J, Holmberg L, Bergkvist L, Wolk A. Red meat consumption and risk of cancers of the proximal colon, distal colon and rectum: the Swedish Mammography Cohort. Int J Cancer. 2005;113:829–34.
6. Norat T, Bingham S, Ferrari P, Slimani N, Jenab M, Mazuir M, et al. Meat, fish, and colorectal cancer risk: the European prospective investigation into cancer and nutrition. J Natl Cancer Inst. 2005;97:906–16.
7. Newell LE, Heddle JA. The potent colon carcinogen, 1,2- dimethylhydrazine induces mutations primarily in the colon. Mutat Res. 2004;564:1–7.
8. Saini MK, Sharma P, Kaur J, Sanyal SN. The cyclooxygenase-2 inhibitor etoricoxib is a potent chemopreventive agent of colon carcinogenesis in the rat model. J Environ Pathol Toxicol Oncol. 2009;28:39–46.
9. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993;363:558–61.
10. Fiala E. Investigations into the metabolism and mode of action of the colon carcinogen 1, 2-dimethylhydrazine. Cancer. 1975;36:2407–12.
11. Andersen V, Vogel U. Systematic review: interactions between aspirin, and other nonsteroidal anti-inflammatory drugs, and polymorphisms in relation to colorectal cancer. Aliment Pharmacol Ther. 2014;40:147–59.
12. Wang D, Dubois RN. Prostaglandins and cancer. Gut. 2006;55(1):115–22.
13. Bosetti C, Gallus S, Vecchia C. Aspirin and cancer risk: a summary review to 2007. Cancer Res. 2009;181:231–51.
14. Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, et al. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr. 2000;130:467S–71S.
15. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31–41.
16. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995;55:3785–9.
17. Fosslien E. Molecular pathology of cyclooxygenases-2 in neoplasia. Ann Clin Lab Sci. 2000;30:3–21.
18. Ashktorab H, Dawkins FW, Mohamed R, Larbi D, Smoot DT. Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma cells. Dig Dis Sci. 2005;6:1025–32.
19. Seung JM, Kim HI. Role of prostaglandins in colon cancer. Korean J Gastroenterol. 2008;51:274–9.
20. Peter CE, Alison MG, Garry GD, Mur L, Morgan G. Aspirin, salicylates, and cancer. Lancet. 2009;373:1301–9.
21. Perez-Garcia F, Adzet T, Canigueral S. Activity of artichoke leaf extract on reactive oxygen species in human leukocytes. Free Radic Res. 2000;33:661–5.
22. Lee LT, Huang YT, Hwang JJ, Lee PP, Ke FC, Nair MP, et al. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and apoptosis of pancreatic tumor cells. Anticancer Res. 2002;22(3):1615–27.
23. Samy RP, Gopalakrishnan P, Ignacimuthu S. Anti-tumor promoting potential of luteolin against 7, 12-dimethylbenz (a) anthracene-induced mammary tumors in rats. Chem Biol Interact. 2006;164(1–2):1–14.
24. Ashokkumar P, Sudhandiran G. Protective role of luteolin on the status of lipid peroxidation and antioxidant defense against azoxymethane-induced experimental colon carcinogenesis. Biomed Pharmacother. 2008;62:590–7.
25. Manju V, Nalini N. Chemopreventive potential of luteolin during colon carcinogenesis induced by 1,2-dimethylhydrazine. Ital J Biochem. 2005;54:268–75.
26. Nalini N, Manju V, Menon VP. Effect of coconut cake on the bacterial enzyme activity in 1,2-dimethylhydrazine induced colon cancer. Clin Chim Acta. 2004;342:203–10.
27. Davis A, Patterson F. Aspirin reduces the incidence of colonic carcinoma in the dimethylhydrazine rat animal model. Intern Med J. 2008;24(3):301–3.
28. Mahmoud NN, Dannenberg AJ, Mestre J, Bilinski RT, Churchill MR, Martucci C, et al. Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery. 1998;124(2):225–31.
29. Anastasia K, Angeliki X, Eleni E, Panagiota K, Theodore T, Andreas P, et al. Luteolin reduces lipopolysaccharide induced lethal toxicity and expression of proinflammatory molecules in mice. Am J Respir Crit Care Med. 2002;165:818–23.
30. Schirmeister J. Determination of creatinine in serum. Dtsch Med Wschr. 1964;89:1940.
31. Fawcett JK, Scott JE. J Clin Pathol. 1960;13:156–9.
32. Barham D, Trinder P. An improved colour reagent for the determination of blood glucose by the oxidase system. Analyst. 1972;97(151):142–5.
33. Yoshioka T, Kawada K, Shimada T, Mori M. Lipid peroxidation in maternal and cord blood and protective mechanism against activated oxygen toxicity in the blood. Am J Obstet Gynecol. 1979;135:372–6.
34. Minami AM, Yoshikawa H. A simplified assay method of superoxide dismutase activity for clinical use. Clin Chim Acta. 1979;92(3):337–42.
35. Sinha AK. Colorimetric assay of catalase. Anal Biochem. 1972;47(2):389–94.
36. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967;70:158–69.
37. Beutler E, Duron O, et al. Improved method for the determination of blood glutathione. J Lab Clin Med. 1963;61:882–8.
38. Goldberg, D.M. and Spooner, R. J. (1983). in Methods of enzymatic analysis (Bergmeyen, H.V. Ed.) 3rd edn. 3: 258 – 265.Verlog Chemie, Deerfield beach, FI.
39. Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem. 1974;249:7130–9.
40. Khan R, Sultana S. Farnesol attenuates 1,2-dimethylhydrazine induced oxidative stress, inflammation and apoptotic responses in the colon of Wistar rats. Chem Biol Interact. 2011;192:193–200.
41. Shiptz B, Klein E, Bklan G, Neufeld D, Nissan A, Freund HR, et al. Suppressive effects of aspirin on aberrant crypt foci in patients with colorectal cancer. Gut. 2003;52:1598–601.
42. Manju V, Balasubramaniyan V, Nalini N. Rat colonic lipid peroxidation and antioxidant status: the effects of dietary luteolin on 1,2-dimethylhydrazine. Chall Cell Mol Biol Lett. 2005;10:535–51.
43. Fiala ES, Sohn OS, Hamilton SR. Effects of chronic dietary ethanol on in vivo and in vitro metabolism of methylazoxymethanol and on methylazoxymethanol-induced DNA methylation in the rat colon and liver. Cancer Res. 1987;47:5939–43.
44. Bhatnagar J, Tewari H, Bhatnagar M, Austin GE. Comparison of carcinoembryonic antigen in tissue and serum with grade and stage of colon cancer. Anticancer Res. 1999;19:2181–8.
45. Umesalma S, Sudhandiran G. Differential inhibitory effects of the polyphenol ellagic acid on inflammatory mediators NF-kappaB, iNOS, COX-2, TNF-alpha, and IL-6 in 1, 2-dimethylhydrazine-induced rat colon carcinogenesis. Basic Clin Pharmacol Toxicol. 2010;107:650–5. journal compilation _ 2010 Nordic Pharmacological Society.
46. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183–8.
47. Taketo MM. COX-2 and colon cancer. Inflamm Res. 1998;47:112–6.
48. Kuznietsova HM, Ogloblya OV, Rybalchenko VK. Impact of dihydropyrrol derivative on the normal colonic mucosa of DMH-induced colon cancer rats compared with 5 fluorouracil. Exp Oncol. 2013;35(1):25–9.
49. Khan R, Khan AQ, Lateef A, Rehman MU, Tahir M, Hamiza OO, et al. Glycyrrhizic acid suppresses the development of precancerous lesions via regulating the hyperproliferation, inflammation, angiogenesis and apoptosis in the colon of Wistar rats. PLoS ONE. 2013;8(2):1–22 e56020.
50. Sharma P, Kaur J, Sanyal SN. Effect of etoricoxib, a cyclooxygenase-2 selective inhibitor on aberrant crypt formation and apoptosis in 1,2 dimethyl hydrazine induced colon carcinogenesis in rat model. Nutr Hosp. 2010;25(1):39–48.
51. Sengottuvelan M, Senthilkumar R, Nalini N. Modulatory influence of dietary resveratrol during different phases of 1, 2-dimethylhydrazine induced mucosal lipid-peroxidation, antioxidant status and aberrant crypt foci development in rat colon carcinogenesis. Biochim Biophys Acta. 2006;1760:1175–83.
52. Nandhakumar R, Salini K, Niranjali Devaraj S. Morin augments anticarcinogenic and antiproliferative efficacy against 7,12- dimethylbenz(a)-anthracene induced experimental mammary carcinogenesis. Mol Cell Biochem. 2012;364:79–92.
53. Rajeshkumar NV, Kuttan R. Modulation of carcinogenic response and antioxidant enzymes of rats administered with 1,2-dimethylhydrazine by Picroliv. Cancer Lett. 2003;191:137–43.
54. Khan R, Khan AQ, Qamar W, Lateef A, Tahir M, Rehman MU, et al. Chrysin protects against cisplatin-induced colon. toxicity via amelioration of oxidative stress and apoptosis: probable role of p38MAPK and p53. Toxicol Appl Pharmacol. 2012;258:315–29.
55. Kharchuk IV, Filins'ka OM, Iablons'ka SV, Rybal'chenko VK, Fiziolohichnyi Z. Effect of maleimide derivative on the morpho-functional state of the kidney in experimental colon carcinogenesis in rats. Fiziol Zh. 2010;56(6):62–9.
56. Vladimir S, Turusov, Chemeris GY. Renal cell tumors induced in CBA male mice by 1,2-dimethylhydrazine. Toxicol Pathol. 1992;20(4):570–5.
57. Mostafa SA. Effect of allyl alcohol as a glutathione depleting agent on carbohydrate metabolism in rat. Egypt J Ger Soc Zool. 1998;26(A):13–34.
58. Michael JT, Mohan MN, Eugenia E. Aspirin use and risk of fatal cancer. Am Cancer Soc. 1992;53:322–7.
59. Nishihara R, Lochhead P, Kuchiba A, Yamauchi M, Liao X, Imamura Y, et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA. 2013;309:2563–71.
60. Chang HC, Weng CF. Cyclooxygenase-2 level and culture conditions influence NS398-induced apoptosis and caspase activation in lung cancer cells. Oncol Rep. 2001;8:1321–5.
61. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60:1306–11.
62. Davis A, Patterson F. Aspirin reduces the incidence of colonic carcinoma in the dimethylhydrazine rat animal model. Aust NZ J Med. 1994;24(3):301–3.
63. Miliaras S, Miliaras D, Vrettou E, Zavitsanakis A, Kiskinis D. The effect of aspirin and high fibre diet on colorectal carcinoma: a comparative experimental study. Tech Coloproctol. 2004;8:59–61.
64. Craven PA, De Rubertis FR. Effect of aspirin on 1,2 DMH induced colonic carcinogenesis. Carcinogenesis. 1992;4:541–6.
65. Rosenberg L, Louik C, Shapiro S. Nonsteroidal anti- inflammatory drug use and reduced risk of large bowel cancer. Cancer. 1998;82:2326–33.
66. Kanwar SS, Vaiphei K, Nehru B, Sanyal SN. Chemopreventive effects of nonsteroidal anti-inflammatory drugs in the membrane lipid composition and fluidity parameters of the 1,2-dimethylhydrazine-induced colon carcinogenesis in rats. Drug Chem Toxicol. 2007;30:293–309.
67. Kanwar SS, Vaiphei K, Nehru B, Sanyal SN. Antioxidative effects of nonsteroidal anti-inflammatory drugs during the initiation stages of experimental colon carcinogenesis in rats. J Environ Pathol Toxicol Oncol. 2008;27:89–100.
68. Marcela, C. T., Maria I. B., Jorge S. and Paulo M Hoff (2014): Primary prevention of colorectal cancer: myth or reality? WJG 20th Anniversary Special Issues (5): Colorectal cancer, 1-27.
69. Hall, J.E. (2011). Textbook of medical physiology. 12th ed. Philadelphia: Saunders Elsevier;p 307- 326.
70. Naughton CA. Drug induced nephrotoxicity. Am Fam Physician. 2008;78(6):743–50.
71. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J. 1988;296(6618):313–6.
72. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984;310:563–72.
73. Gilman EA, Langman MJ, Cheng KK, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ. 2000;320:1642–6.
74. Luigi, D.L.; Laura, G.; Francesco, R.; Carlo, B. and Domenico, C. (2001): Aspirin, exercise and pituitary hormones. Official J. Am. College Sports Med., p2029-2035.
75. Taj S, Nagarajan B. Inhibition by quercetin and luteolin of chromosomal alterations induced by salted, deep-fried fish and mutton in rats. Mutat Res. 1996;369(1, 2):97–106.
76. Manju V, Nalini N. Effect of luteolin on glycoproteins metabolism in 1, 2-dimethylhydrazine induced experimental colon carcinogenesis. J Biochem Tech. 2009;1(2):57–61.
77. Yoon JH, Baek SJ. Molecular targets of dietary polyphenols with anti-inflammatory properties. Yonsei Med J. 2005;46:58596.
78. Iwashita K, Kobori M, Yamaki K, Tsushida T. Flavonoids inhibit cell growth and induce apoptosis in B16 melanoma 4A5 cells. Biosci Biotechnol Biochem. 2000;64:1813–20.
79. Mutoh M, Takahashi M, Fukuda K, Komatsu H, Enya T, Matsushima-Hibiya Y, et al. Suppression by flavonoids of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells: structure-activity relationship. Jpn J Cancer Res. 2000;91:686–91.
80. Robak J, Shridi F, Wolbis M, Krolikowska M. Screening of the influence of flavonoids on lipoxygenase and cyclooxygenase activity, as well as on nonenzymic lipid oxidation. Pol J Pharmacol Pharm. 1988;40:451–8.
81. Segal R, Lubart E, Leibovitz A, Iaina A, Caspi D. Renal effects of low dose aspirin in elderly patients. IMAJ. 2006;8:679–82.
82. Masroor MI, Elmi AH, Butt GD, Khan SJ. Low dose aspirin prophylaxis for cardiovascular disease in the elderly population: is it safe for the kidney? Ann Pak Inst Med Sci. 2010;6(1):11–4.
83. Chiang CT, Way TD, Lin JK. Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21(WAF1/CIP1) expression with rapamycin. Mol Cancer Ther. 2007;6:2127–38.
84. Kang KP, Park SK, Kim DH, Sung MJ, Jung YJ, Lee JE, et al. Luteolin ameliorates cisplatin-induced acute kidney injury in mice by regulation of p53-dependent renal tubular apoptosis. Nephrol Dial Transplant. 2011;26:814–22.
85. McCord JM. The evolution of free radicals and oxidative stress. Am J Med. 2000;108(8):652–9.
86. Lien EJ, Ren S, Bui HH, Wang R. Quantitative structure-activity relationship analysis of phenolic antioxidants. Free Radic Biol Med. 1999;26:285–94.
87. Ross JA, Kasum CM. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr. 2002;22:19–34.
88. Ueda H, Yamazaki C, Yamazaki M. Luteolin as an anti- inflammatory and anti-allergic constituent of Perilla frutescens. Biol Pharm Bull. 2002;25:1197–202.
89. Cao G, Sofic E, Prior RL. Antioxidant and prooxidant behavior of flavonoids: structure-activity relationships. Free Radic Biol Med. 1997;22:749–60.